CVS Health Corporation (CVS) Is a Trending Stock: Facts to Know Before Betting on It

CVS Health (CVS) has demonstrated strong market performance, with its shares rising 16.2% over the past month, significantly outperforming the S&P 500. The company is projected for continued growth, with current fiscal year EPS estimated at $6.32 (+16.6% YoY) and next fiscal year at $7.14 (+12.9% YoY), underpinned by consistent revenue and earnings beats in recent quarters. This positive fundamental outlook, driven by favorable earnings estimate revisions, has resulted in a Zacks Rank #2 (Buy) rating and an 'A' Zacks Value Style Score, suggesting potential near-term outperformance and a discounted valuation relative to its peers.

Analysis

CVS Health has demonstrated significant recent market outperformance, with its stock appreciating 16.2% over the past month, substantially outpacing the S&P 500 composite's 1.9% gain. This momentum is supported by a bullish outlook on earnings, with analysts revising full-year estimates upward. The consensus EPS estimate for the current fiscal year has risen 4% in the last 30 days to $6.32, projecting a 16.6% year-over-year increase. Forecasts for the next fiscal year are also positive, with an estimated 12.9% EPS growth to $7.14. This contrasts with a minor negative revision of -3.4% for the current quarter's consensus estimate, although that quarter is still expected to show 26.6% YoY EPS growth. The company's execution has been strong, having exceeded consensus EPS and revenue estimates for the last four consecutive quarters; in the most recent quarter, it reported a 23.13% EPS surprise and a 5.54% revenue surprise on 8.4% YoY revenue growth. Coupled with a Zacks Rank #2 (Buy) rating and an 'A' for Value Style Score, the data suggests the stock is viewed as having potential for near-term outperformance while trading at a discount to its peers.

Key Decisions for Investors

• Given the positive full-year earnings revisions, consistent history of beating consensus, and a 'Buy' rating from the source, investors could view CVS as a candidate for potential near-term capital appreciation.
• The stock's 'A' grade for value indicates it may be trading at a discount to peers, suggesting a possible entry point for value-oriented investors who are also seeking exposure to double-digit forward earnings growth.
• It is prudent to monitor the current quarter's earnings estimates, which have seen a minor -3.4% downward revision, as this could be an early indicator of shifting near-term business trends despite the strong annual outlook.